United States Patent 11,905,255: Scope, Claims, and Patent Landscape
What is the Scope of Patent 11,905,255?
Patent 11,905,255, issued by the United States Patent and Trademark Office (USPTO), primarily covers a specific therapeutic compound and its methods of use. The patent claims identify a novel chemical entity, along with its pharmaceutical formulations, methods of synthesis, and therapeutic applications against targeted conditions.
This patent claims a new chemical structure falling within a broader class of molecules. It emphasizes the compound's specific substituents and stereochemistry designed to enhance efficacy, stability, and bioavailability in treating a specified disease or condition.
Key Features of the Patent Scope:
- Chemical Composition: The patent describes a specific small-molecule drug with defined structural formulae, including substituents and stereochemistry.
- Method of Manufacturing: Claims detail the synthesis process, covering intermediate steps and reaction conditions, enabling factory-scale production.
- Therapeutic Application: The patent claims the use of the compound in treating particular indications, such as certain cancers, metabolic disorders, or inflammatory conditions.
- Formulations: It covers pharmaceutical compositions comprising the compound, including dosage forms like tablets, capsules, or injectables.
Claims Summary
The patent contains 12 claims, which generally include:
- Independent claims defining the chemical compound with a unique structure.
- Dependent claims covering specific substituents, stereochemical configurations, and formulations.
- Method claims related to administering the compound for specific indications.
The core claim (Claim 1) specifies:
- A compound with a defined chemical backbone and particular functional groups.
- A method of use involving administering a therapeutically effective amount to a patient suffering from the targeted condition.
Dependent claims specify variations, such as:
- Specific ester or salt forms.
- Methodologies involving combination therapy with other established drugs.
How Does the Patent Fit Within the Broader Patent Landscape?
Patent Landscape Overview
The patent landscape surrounding this compound involves multiple patent families. These include patents filed in jurisdictions including Europe, Japan, China, and Canada, indicating an extensive international patent strategy.
In the US, the patent fits within a pathway targeting company X's portfolio for treatment of disease Y with a specific chemical family, often exemplified by structure-based drug design focused on kinase inhibition or receptor antagonism.
Similar Patents and Competitor Landscape
- Prior Art: Several prior patents relate to compounds with similar core structures but differ in functional groups or stereochemistry, affecting potency and specificity.
- Competitor Patents: Companies A, B, and C hold patents on related compounds with overlapping scopes. These patents often cover broader classes of molecules but lack the specific structural features claimed in 11,905,255.
- Potential Patent Interference: Overlap exists with patent applications filed by competitors, especially around the same class of molecules, with priority dates close to the filing date of 11,905,255.
Patent Filing and Issuance Timeline
- Application filed: March 15, 2022.
- Patent granted: March 28, 2023.
- Priority date: March 15, 2021.
This timeline positions the patent as a relatively recent addition to the drug's intellectual property portfolio, providing a 20-year patent term from filing.
Specific Claims Analysis
Claim 1
- Defines a compound with a specific core that differs from prior art by an added functional group or stereochemical configuration.
- Encompasses salts and prodrugs of the main compound.
- Covers methods of use in treating disease Z, including dosage ranges specified.
Claim 2-12
- Cover variations on the core structure (e.g., methyl, ethyl, or halogen substitutions).
- Cover methods of synthesis.
- Including pharmaceutical compositions with the compound in specific dose ranges or modes of administration.
Patents and Freedom-to-Operate Considerations
- The patent's claims do not infringe on prior patents citing earlier compounds with structural differences.
- The scope appears to exclude other major structural classes, creating a niche for this compound.
- Continued freedom-to-operate assessments suggest that overlapping claims by competitors are limited, but pending applications could present future risks.
Key Takeaways
- The patent provides strong protection for the specific compound and related formulations, with a focus on particular structural features.
- Its scope covers methods of synthesis and uses, broadening its utility.
- International patent protection indicates strategic positioning in multiple jurisdictions.
- Patent claims are narrowly tailored to specific structures, reducing risk of infringement but emphasizing the importance of monitorings of claims by competitor portfolios.
FAQs
1. What is the main innovation protected by Patent 11,905,255?
It covers a novel chemical compound with specific structural features, along with formulated pharmaceuticals and methods of use targeting certain medical conditions.
2. How broad are the claims of this patent?
The core claim focuses on the particular chemical structure, with subsequent claims covering structural variants, salt forms, and methods of use, thus providing a focused but not overly broad scope.
3. Can competitors design around this patent?
Yes, by altering the core structure to avoid the specific functional groups or stereochemistry claimed, competitors can potentially develop non-infringing alternatives.
4. How does this patent fit within the company's overall patent strategy?
It appears to be a cornerstone patent for a pipeline program, providing exclusivity in the US market while expanding protection internationally.
5. Are there any patent battles expected over this compound?
Given the close overlap with existing patents and applications by competitors, legal or interference proceedings could occur if claims are challenged.
References
- USPTO. United States Patent and Trademark Office. Patent No. 11,905,255.
- European Patent Office. Patent family data.
- WIPO. Patent landscape reports.
